4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

Company Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.86 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.84, and compared to a loss of $0.66 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $0.01 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 98.70%, and down from $0.03 million in the same quarter last year [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates [2] Stock Performance - 4D Molecular Therapeutics shares have declined approximately 44.1% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $1.08 million, and for the current fiscal year, it is -$3.40 on revenues of $8.47 million [7] Industry Outlook - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact the stock's future performance [5]